News

The approval, which was was supported by data from a 56-week trial involving 223 obese individuals 12-17 years old, recommended the capsules be used in conjunction with a reduced-calorie diet and increased physical activity.

The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.

There were several risk factors for generalized anxiety disorder including being a health care worker, having a chronic illness, and fear of contracting COVID-19.

At HiD 2022, Dr. Budoff discusses the use and utility of coronary calcium scoring for risk stratification

"The challenges of an existing rheumatologist workforce shortage, changing workforce demographics, and physician burnout have been compounded by the COVID-19 pandemic."

Those with a first-degree female relative with PPD history were more than 2.5 times likelier to have PPD.

Dr. Martin explores the explosion of new consumer technologies and how to close the gap in disparities between data collection and using the data in practice.

Field leader Carla Lamb, MD, discusses advances to evaluating and treating chronic diseases including lung cancer and COPD in this latest episode.

Dr. Rindos emphasizes the importance of referring patients to an OBGYN if they're experiencing heavy bleeding or painful cramping.

Dr. Ray discusses the impact of current practice on cholesterol goal attainment and what more needs to be done.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2022.

Dr. Green discusses the potential of combination therapy to reduce cardiovascular and kidney outcomes in people with type 2 diabetes.

Dr. Joseph discusses modalities to address cardiometabolic disease in individuals around the country, from lifestyle management to policy-level changes.

Despite the frequency in which the ARAs were detected, investigators noted that they were not associated with any noticeable patient outcomes.

The Acne-Q and the CompAQ instruments received an “A” recommendation by investigators, though evidence on content validity and other measurement properties were lacking.

Abortion is much safer than having a term delivery and actually reduces the patient's chance of death–from a purely scientific perspective, which Aziz said, is the perspective all physicians should hold when they approach difficult situations.

Teodora Staeva, PhD, discusses how Lupus Research Alliance's is recognizing the critical contributions of underrepresented minority researchers through their Diversity in Lupus Research Award.

Dr. Rindos discusses the intricacies of diagnosing and treating uterine fibroids, which develop in the majority of women.

Between 2015-2019 the number of HBV-related deaths increased by 2.9%.

In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

New data suggest a combination of cosmetic and psychiatric care for patients with the chronic pigmentation condition may provide multi-systemic benefit.

Dr. Craiglow speaks on how dermatologists can set expectations with their patients regarding the effectiveness and timeliness of current vitiligo therapies,

Dr. Karan Lal speaks on treating vitiligo in patients from across the world, and how he expects a wave of prescription requests for ruxolitinib cream following the potential FDA approval.

Dr. Cohen of Yale details new therapeutic strategies and the different cultural perspectives regarding vitiligo.

"Remote care interventions have become more widespread over the past 20 years, with presumed benefits for diagnosis, treatment, rehabilitation and follow-up monitoring of patients.”

An updated review highlights both the efficacy and safety of the increasingly popular vitiligo treatment.

The issued marketing denial orders require the country's most popular vaping device company remove all commercial products on the basis of insufficient toxicity data.

Many patients with vitiligo have become disillusioned with healthcare due to a lack of long-term, effective management strategies. However, Dr. Chovatiya believes the impending ruxolitinib cream approval may signal real change in the treatment of the skin disorder.

SLE-dysregulated genes were linked to biological functions and gene networks, including regulation of type I interferon-mediated signaling pathway, response to steroid hormone, and response to hypoxia.